RGS 0.00% 0.5¢ regeneus ltd

Japanese patent, European classification, Significantly positive...

  1. 172 Posts.
    lightbulb Created with Sketch. 52
    Japanese patent,
    European classification,
    Significantly positive results for Phase I trials,
    Japanese Partner,
    Japanese Director.

    RGS is not the most exciting biotech when it comes to communication, but it's hard to deny they deliver on promises.

    And all financial indicators are now very positive, creating the opportunity to finance (borrow?) their commercialisation plan in Japan and Europe: communication, marketing, sales.

    Well done.
 
watchlist Created with Sketch. Add RGS (ASX) to my watchlist
(20min delay)
Last
0.5¢
Change
0.000(0.00%)
Mkt cap ! $1.532M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
6 914255 0.5¢
 

Sellers (Offers)

Price($) Vol. No.
0.6¢ 582195 6
View Market Depth
Last trade - 19.00pm 29/03/2024 (20 minute delay) ?
Last
0.5¢
  Change
0.000 ( 0.00 %)
Open High Low Volume
0.5¢ 0.5¢ 0.5¢ 13888
Last updated 15.27pm 29/03/2024 ?
RGS (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.